Condition: Alzheimer Disease · Sponsor: NSC-Therapeutics
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
This description comes directly from the study's public registry record.
Barbara Fridrich, DI · 004366488869909 · bfridrichl@neuroscios.com
Klara Fuereder, MSC · 00436645472844 · kfuereder@neuroscios.com
Always discuss trial participation with your own doctor first.
| Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft GmbH | Salzburg, State of Salzburg, Austria | Recruiting |
| University Hospital Graz | Graz, Styria, Austria | Recruiting |
| Medical University Innsbruck | Innsbruck, Austria | Recruiting |
| Medical University Vienna | Vienna, Austria | Recruiting |
| Clinic Altenburger Land GmbH | Altenburg, Germany | Not Yet Recruiting |
| Zentrum fuer klinische Forschung Dr. I. Schoell GmbH | Bad Homburg, Germany | Recruiting |
| University Clinic Köln | Cologne, Germany | Recruiting |
| Universitaetsmedizin Goettingen | Göttingen, Germany | Recruiting |
| Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit | Mannheim, Germany | Recruiting |
| SANOS Clinic | Ratingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06995573